Showing Results for
- Academic Journals (51)
Search Results
- 51
Academic Journals
- 51
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Raewyn M Seaberg (corresponding author) [1, 6]; Simon R Smukler [1, 6]; Timothy J Kieffer [2]; Grigori Enikolopov [3]; Zeenat Asghar [4]; Michael B Wheeler [4]; Gregory Korbutt [5]; Derek van der Kooy [1]...
- 2From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Maxwell Gordon [1] To the editor: Your July issue contains an extraordinarily flawed review of a book that attempts to rehabilitate the scientific reputation of Peter Duesberg. The latter asserts that HIV...
- 3From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Alla Katsnelson [1] Despite Russian efforts to upgrade its intellectual property (IP) legislation, issues related to enforcement of IP protection are still high on the agenda of the working party on Russia's...
- 4From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedNew stock option reporting In late July, the US House of Representatives passed the Stock Option Reform Act (H.R. 3574), which limits reporting of stock options to those allocated to a company's CEO and its four other...
- 5From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor Affiliations: New stock option reporting In late July, the US House of Representatives passed the Stock Option Reform Act (H.R. 3574), which limits reporting of stock options to those allocated to a company's...
- 6From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Mathias Ricker [1] Article 52(4) of the European Patent Convention stipulates that "Diagnostic methods practiced on the human or animal body shall not be regarded as inventions which are susceptible of...
- 7From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor Affiliations: Recent patent applications in autoimmune disease research Table 1 Recent patent applications in autoimmune disease research WO 200456857 A new variant of the Yin Yang-1 transcription...
- 8From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Shin-ichi Hashimoto [1]; Yutaka Suzuki [2, 4]; Yasuhiro Kasai [3, 4]; Kei Morohoshi [1]; Tomoyuki Yamada [3]; Jun Sese [3]; Shinichi Morishita [3]; Sumio Sugano [2]; Kouji Matsushima (corresponding author) [1]...
- 9From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Emilie Balcon [1] French interior minister Nicolas Sarkozy recently announced that the draft for the 2005 budget, to be voted on by January 1, 2005, will include new measures to support the creation of four...
- 10From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Cormac Sheridan [1] Biotech companies that base their business strategy on orphan drug development are bracing themselves for a European Commission (EC) report on orphan drug pricing. EC officials are...
- 11From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Karl A Thiel [1] The only two sure things in life, the saying goes, are death and taxes. Have pity, then, for the poor biotech startup, which can't even count on the latter. Most discovery-based companies...
- 12From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Gregory A Daniels [1, 2, 8]; Luis Sanchez-Perez [1, 3, 8]; Rosa Maria Diaz [1, 3]; Timothy Kottke [1]; Jill Thompson [1]; Maoyi Lai [1]; Michael Gough [1, 3]; Mahzuz Karim [4]; Andrew Bushell [4]; Heung Chong...
- 13From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Jeffrey L. Fox [1] A report released on July 28 by a 13-member committee of the Institute of Medicine within the National Academy of Sciences (NAS) in Washington, DC, proposes to extend voluntary testing to...
- 14From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Mark Ratner [1] Oncology company OSI Pharmaceuticals of Melville, NY, announced, on August 11, its intention to cut 90 of its UK employees, 18% of its workforce, mostly in research, to save $10-15 million....
- 15From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Laurent Jespers [1, 3, 4]; Oliver Schon [1, 3, 4]; Kristoffer Famm [2]; Greg Winter (corresponding author) [1, 2] We describe a method for selecting aggregation-resistant proteins by heat denaturation. This...
- 16From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Manfred Ringpfeil [1] To the editor: Stephan Herrera's article "Industrial biotechnology--a chance at redemption" (Nat. Biotechnol. 22, 671-675, 2004) ends: "Without government prodding...this green dream...
- 17From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Soldano Ferrone [1] Tumor immunologists have assumed over the past 15 years that one needs to identify and characterize tumor antigens to develop vaccines for the immunization of patients with malignant...
- 18From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Sean R Eddy [1] There are excellent introductory books on Bayesian analysis [1, 2, 3], but the key ideas behind the buzzword can be grasped quickly. Consider the following gambling puzzle--one that has...
- 19From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Peter Mitchell [1] On August 2, antibody company Immunomedics, in Morris Plains, New Jersey, raised $15 million through a form of financing that has gained momentum over the past few years, called a...
- 20From: Nature Biotechnology. (Vol. 22, Issue 9) Peer-ReviewedAuthor(s): Harry J Gilbert [1]; Anthony G O'Donnell [2]; John C Mathers [3, 4] To the Editor: The Perspective of Nielsen and Townsend on p. 1110 presents an interesting analysis of current studies on horizontal gene...